Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals

AIDS

Volumn 15, Issue 18, 2001, Pages 2379-2384

  Phillips, A N ^a   Miller, V ^a   Sabin, C ^a   Cozzi Lepri, A ^a   Klauke, S ^a   Bickel, M ^a   Doerr, H W ^a   Hill, A ^a   Staszewski, S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

HAART; Long term follow up; Viral load; Viral rebound; Viral suppression

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; COMORBIDITY; DRUG EFFICACY; FEMALE; FOLLOW UP; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0035824741     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200112070-00005     Document Type: Article

References (33)

1. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro SIDA Study Group
4. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
5. AIDS-related opportunistic illnesses after initiation of potent antiretroviral therapy
6. AIDS across Europe, 1994-98: The EuroSIDA study
7. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
8. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
9. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
10. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy
11. Risk of new AIDS diseases in people on triple therapy
12. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA ar the nadir
13. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
14. Detectable HIV-1 RNA ar levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy
15. Predictors of optimal virological response to potent antiretroviral therapy
16. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantification
17. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
18. Low two-year risk of virologic failure with first regimen HAART
19. START Observational study: Longitudinal follow-up of virologic and immunologic responses in START I and START II patients
20. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance
21. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
22. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA Study
23. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
24. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
25. Statistical models in epidemiology
26. Virological response to protease inhibitor therapy in an HIV clinic cohort
27. Impact of directly observed therapy on long-term outcomes in HIV clinical trials
28. Low level HIV viral rebound and blips in patients receiving potent antiretroviral therapy
29. HIV suppression and risk of drug resistance mutations
30. Mechanisms of Immune Reconstitutio on Potent ART
31. Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy